Literature DB >> 15583854

Kit as a human oncogenic tyrosine kinase.

Y Kitamura1, S Hirotab.   

Abstract

Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs). Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells. Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans. The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate. The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs. Kit is interesting from both a biological and clinical view-point.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583854     DOI: 10.1007/s00018-004-4273-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  62 in total

Review 1.  Histopathology of gastrointestinal stromal tumor.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  J Surg Oncol       Date:  2011-12       Impact factor: 3.454

2.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

4.  Myoelectric activity and motility of the Roux limb after cut or uncut Roux-en-Y gastrojejunostomy.

Authors:  Ying-Mei Zhang; Xiu-Li Liu; Dong-Bo Xue; Yun-Wei Wei; Xiao-Guang Yun
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

5.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

6.  Involvement of Fyn kinase in Kit and integrin-mediated Rac activation, cytoskeletal reorganization, and chemotaxis of mast cells.

Authors:  Lionel A Samayawardhena; Reuben Kapur; Andrew W B Craig
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 7.  Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.

Authors:  Hung Nguyen; David Aum; Sherwin Mashkouri; Gautam Rao; Juan Diego Vega Gonzales-Portillo; Stephanny Reyes; Cesario V Borlongan
Journal:  Expert Rev Neurother       Date:  2016-05-13       Impact factor: 4.618

8.  Diagnostic challenges of motility disorders: optimal detection of CD117+ interstitial cells of Cajal.

Authors:  Megan M Garrity; Simon J Gibbons; Thomas C Smyrk; Jean Marie Vanderwinden; Pedro Julian Gomez-Pinilla; Anoop Nehra; Matthew Borg; Gianrico Farrugia
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

9.  Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

Authors:  Adhemar Longatto-Filho; Céline Pinheiro; Olga Martinho; Marise A R Moreira; Luiz F J Ribeiro; Geraldo S Queiroz; Fernando C Schmitt; Fátima Baltazar; Rui M Reis
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

10.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Authors:  D Handolias; A L Hamilton; R Salemi; A Tan; K Moodie; L Kerr; A Dobrovic; G A McArthur
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.